Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous NephropathyGlobeNewsWire • 06/30/25
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMAGlobeNewsWire • 06/27/25
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 ResultsGlobeNewsWire • 06/25/25
20 companies in the S&P 500 whose investors have gained the greatest rewards from stock buybacksMarket Watch • 06/18/25
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich AtaxiaGlobeNewsWire • 06/18/25
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease ActivityGlobeNewsWire • 06/12/25
Biogen Inc. (BIIB) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 06/10/25
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of DirectorsGlobeNewsWire • 06/03/25
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based TherapiesGlobeNewsWire • 05/27/25
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - YetSeeking Alpha • 05/12/25
Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior PrincipalGlobeNewsWire • 05/12/25
BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance CutZacks Investment Research • 05/01/25
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 05/01/25
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales SoarInvestors Business Daily • 05/01/25
Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 04/30/25